RELB and breast cancer: BRD4 degrader reduced BRD4, PD-L1, RelB, and IL-6 levels and overexpression of PD-L1 of ARV-825 treated breast cancers increased reduced PD-L1, RelB, and IL-6 levels (Fig. 6F).